PHILADELPHIA — Women being treated for breast cancer with aromatase inhibitors may experience extremely low estrogen levels resulting in a wide variety of side effects that a typical postmenopausal woman without cancer may not experience.
Data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Conference, held here Nov. 7-10, 2010, showed that women assigned to take aromatase inhibitors had increases in side effects such as hot flashes, decreased appetite, fatigue, fever, breast sensitivity, etc.
"Aromastase inhibitors represent one of the most major advances in breast cancer treatment," said Lisa Gallicchio, Ph.D., an epidemiologist at The Prevention and Research Center at Mercy Medical Center, Baltimore. "Their incorporation into the breast cancer treatment armamentarium has led to impressive reductions in breast cancer recurrence and mortality rates.
"Despite this, many breast cancer patients stop taking their aromatase inhibitor treatment —which is usually prescribed for five years — or do not adhere to their treatment prescription," she said, adding that this may be due to, at least in part, the side effects associated with the drugs.
To better define the full spectrum of side effects associated with aromatase inhibitor treatment, Gallicchio and colleagues surveyed 100 women with breast cancer who were about to start treatment with aromatase inhibitors. Their side effects were compared with those of 200 similarly-aged women without a history of breast cancer.
Questionnaires about symptoms were completed prior to treatment initiation by women with breast cancer and at the start of the study for the healthy women. Women were followed for six months and completed additional questionnaires at three months and at the completion of the study.
Women taking aromatase inhibitors were five times more likely to report having hot flashes, breast sensitivity and chest pain than healthy women. In addition, they were four times more likely to report night sweats, cold sweats and hair loss and about three times more likely to report leg cramps, weight gain, sleep disturbance, tendency to take naps and forgetfulness. Other increased symptoms included intestinal gas, cough, depression, interrupted sleep and irritability.
"We know that aromatase inhibitors are effective in treating breast cancer," Gallicchio said. "Knowing the side effects of aromatase inhibitor treatment and how to treat them is critical for keeping women on their aromatase inhibitor treatment and improving their chances of surviving and living cancer free."
Download interviews with cancer researchers and recordings of teleconferences by subscribing to the AACR Scientific Podcasts via iTunes (http://www.aacr.org/itunes) or an RSS Reader (http://www.aacr.org/rss).
Follow the AACR on Twitter: @AACR #AACR
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.